Priscoline is indicated for the treatment of persistent pulmonary hypertension of the newborn (“persistent fetal circulation”) when systemic arterial oxygenation cannot be satisfactorily maintained by usual supportive care (supplemental oxygen and/or mechanical ventilation).Priscoline should be used in a highly supervised setting, where vital signs, oxygenation, acid-base status, fluid, and electrolytes can be monitored and maintained.

Priscoline is contraindicated in patients with hypersensitivity to tolazoline.

---

Hypersensitivity -- Altered reactivity to an antigen, which can result in pathologic reactions upon subsequent exposure to that particular antigen.

Priscoline stimulates gastric secretion and may activate stress ulcers.

Through this mechanism, it can produce significant hypochloremic alkalosis.

Pretreatment of infants with antacids may prevent gastrointestinal bleeding.Patients should be observed closely for signs of systemic hypotension, and supportive therapy should be instituted if needed.In patients with mitral stenosis, parenterally administered Priscoline may produce a rise or fall in pulmonary artery pressure and total pulmonary resistance; therefore, it must be used with caution in patients with known or suspected mitral stenosis.